UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of January 2026
Commission
File Number: 001-40678
EUDA
Health Holdings Limited
(Exact
Name of Registrant as Specified in its Charter)
60
Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: +65 6327 1110
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Other
Events.
On
January 13, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.
Exhibits
| 99.1 |
Press release dated January 13, 2026. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| Dated: January
13, 2026 |
|
| |
|
| EUDA
Health Holdings Limited |
|
| |
|
| By: |
/s/
Alfred Lim |
|
| |
Alfred Lim |
|
| |
Chief Executive Officer |
|
Exhibit 99.1
EUDA
Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
SINGAPORE,
Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”),
a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly
owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno
Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range
of diseases in China.
Strategic
Investment and Facility Expansion Plan
Under
the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million
and a second tranche of RMB 5 million, subject to the completion of due diligence, regulatory approvals, and execution of definitive
agreements.
Shenzhen
Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for
stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA’s China strategy, anchoring
EUDA’s regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion
into additional cities and markets.
The
investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen
Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation.
The convertible loan note is expected to carry an interest rate of 6% per annum, payable semi-annually, and may be redeemed with accrued
interest if not converted, subject to the final terms.
Shenzhen
Inno operates a stem cell technology and therapy platform focused on advanced human cell processing, quality controlled cell culture,
precision biological workflows and regulated laboratory operations supporting natural killer cell, gamma delta T cell, cytokine induced
killer cell, mesenchymal stem cell, induced pluripotent stem cell and organoid based programs. The platform integrates biological processing
infrastructure, quality and compliance systems, and scalable operating processes designed to support both clinical and research applications.
Shenzhen
Inno – Strong Institutional Backing
In
August 2017, HSG Capital Group (“HSG”), formerly known as Sequoia Capital China, a leading international venture capital
and private equity firm, strategically invested approximately US$8 million in Shenzhen Inno. The capital provided early institutional
validation of its scientific platform, regulatory foundation, long term commercial potential, and supported the development of its laboratory
infrastructure, quality systems and core technical team.
Mr
Alfred Lim, Chief Executive Officer of EUDA, commented:
“This
agreement reflects our disciplined approach to building long-term stem cell therapy platforms. By supporting the upgrade and expansion
of a high-quality platform using a phased and flexible investment structure, we can validate execution, align our strategies, and create
the foundation for deeper ownership and integration over time. This positions EUDA not only as a healthcare provider, but as a vertically
integrated platform with technology, infrastructure and operational depth.”
About
EUDA Health Holdings Limited
EUDA
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking
Statements
This
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,”
“forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,”
“will,” “should,” “future,” “propose” and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Christensen
Advisory
Christian
Arnell
Phone:
+ 852 9040 0621
Email:
christian.arnell@christensencomms.com
